The reason for this move was not disclosed but it is assumed that the enterprise did not comply with the GMP requirements or violated the Drug Administration regulations. It is surmised that that business impact on the company’s production is not excessive, because the cost of non-compliance is quite low.
China Bio news release, Sept. 18, 2014